Latest Anti Obesity News

Anatara Lifesciences will manufacture an approximately 10,000-capsule demonstration batch of its AOC anti-obesity compound after deciding further pre-clinical work and an immediate clinical trial are not required. The company ended September with $551,000 in cash, helped by a $318,402 R&D tax rebate.

Anatara Lifesciences delivered ambiguous mechanism of action results for its Anti-Obesity Project while reporting statistically significant weight management effects from compound AOC. The company plans a limited Phase 1 study but may delay it amid ongoing strategic discussions, with cash reserves tightening to $0.7 million.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Anatara Lifesciences reports encouraging interim pre-clinical results for its Anti-Obesity Project, with a candidate compound showing significant effects on weight regain and visceral fat in mice. The company also completed a $1.2 million capital raise, bolstering its financial position as it advances research.

Anatara Lifesciences reports encouraging pre-clinical results for its anti-obesity candidate AOC, demonstrating significant reductions in weight regain and visceral fat in mice. However, a delay in mechanism of action studies pushes full data release to January 2026.

Anatara Lifesciences reports steady progress in its anti-obesity pre-clinical studies with results expected by year-end, while preparing its GaRP gastrointestinal health data for publication amid ongoing commercial talks. The company also announces a key board appointment and a $1.2 million capital raise.

Anatara Lifesciences has raised $1.2 million through a discounted share placement to fund its Anti-Obesity project and explore new opportunities. The capital injection reflects strong institutional support amid ongoing pipeline development.

Anatara Lifesciences reported a 35% rise in net loss to $1.95 million for FY25, following pivotal Phase II trial results for its GaRP product that missed the primary efficacy endpoint but showed promising secondary benefits. The company is advancing commercialisation efforts and launching a new anti-obesity project amid tightened cash reserves.

Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.

Anatara Lifesciences has received nearly $1 million from the Australian Government’s R&D tax incentive, providing a vital capital injection to advance its Anti-Obesity pre-clinical studies.

Anatara Lifesciences has strengthened its intellectual property portfolio with a Japanese patent for its GaRP gastrointestinal health product, while progressing pre-clinical studies in its Anti-Obesity Project. The company also confirmed registration of its R&D Tax Incentive application for 2024-2025.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.